Psoriatic arthritis (PsA) is a chronic condition that ... which then affects symptoms, and so on. Treatment for PsA may need to address both the physical and psychological symptoms you’re ...

IL-23, and IL-17 were associated with a lower rate of serious infections among older adults with psoriatic disease, a ...

Noting that the ultimate goal of PsA treatment is prompt reduction of ... bowel disease drives the occurrence of psoriasis or psoriatic arthritis—or whether the reverse is true.

Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects approximately 112 per 100,000 adults worldwide. It ...

Treatment with deucravacitinib in patients with active PsA showed higher response rates and improvement in quality of life ...

Arthritis is one of the most common chronic conditions affecting millions of people worldwide. Yet, many fail to recognize ...

How understanding readiness for change and embracing imperfections can help you break free from old habits, overcome ...

Steqeyma is indicated for the treatment of plaque psoriasis and psoriatic arthritis in adult and pediatric patients, as well ...

Guselkumab is the first and only interleukin-23 inhibitor that offers both subcutaneous and intravenous induction options for ...

Tremfya is also approved to treat patients with plaque psoriasis, active psoriatic arthritis and ulcerative colitis and is ...

IL-23, or IL-17 reduced serious infections, while tofacitinib increased infection risk, according to one study.

The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...